OIRA Conclusion of EO 12866 Regulatory Review

RIN: 0906-AB18         View EO 12866 Meetings	Received Date: 05/24/2018
Title: 340B Drug Pricing Program Ceiling Price and Manufacturer Civil Monetary Penalties Regulation; Further Delay of Effective Date
Agency/Subagency: HHS / HRSA	Stage: Final Rule
Concluded Action: Consistent with Change	Concluded Date: 05/31/2018
Legal Deadline: None	Economically Significant: No
Publication Date: 06/05/2018	Unfunded Mandates: No
Major: No	Related To Homeland Security: No
Regulatory Flexibility Analysis Required: No	Small Entities Affected: No
Federalism Implications: No	Affordable Care Act [Pub. L. 111-148 & 111-152]: No
International Impacts: No	Dodd-Frank Wall Street Reform and Consumer Protection Act, [Pub. L. 111-203]: No
Pandemic Response: Uncollected